1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Urology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
3.Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
4.Department of Urology, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province, Hangzhou 310007, China
Abstract：Objective To analyze the Chinese materia medica compound prescription for the treatment of spermatogenesis in the national patent database and explore the rules of drug concerted application. Methods The Chinese materia medica compound prescription patents for the treatment of spermatorrhea from January 2001 to January 2021 were retrieved from the China Patent Announcement Website, and the data were screened and input into the cloud platform of ancient and modern medical records (V2.3.5). The frequency of use, efficacy, nature, flavour, and channel tropism of the drugs in the compound prescription were analyzed statistically, and the correlation analysis, cluster analysis, and complex network analysis were carried out. Results A total of 170 compound prescription patents were included in the treatment of spermatogenesis, involving 441 kinds of Chinese materia medica. The top five commonly used high-frequency drugs were Lycii Fructus, Rehmanniae Radix Praeparata, Cuscutae Semen, Corni Fructus, Angelicae Sinensis Radix. The compound prescription drugs were mainly deficiency tonifying drugs, and the drugs with the function of tonifying liver and kidney had the highest frequency of use. The most frequently used drugs in the compound prescription were warm drugs, sweet drugs, and drugs that belong to kidney channel. There were six groups with higher frequency of use. Five groups of core drug combinations were obtained by cluster analysis. A core prescription was obtained by complex network analysis. Conclusion The national patent of Chinese materia medica compound prescription is mainly used as tonifying drugs in the treatment of spermatorrhea, which is suitable for the treatment of spermatorrhea caused by deficiency of kidney essence, deficiency of yin and blood, overstrain injuring heart and spleen, deficiency of kidney yin and deficiency of kidney yang. It has certain reference significance for clinical treatment and drug discovery.
魏永强1 高瞻2 高庆和3 陈豪特4 李铭1 程鹏伃1. 基于国家专利的中药复方治疗遗精的用药规律研究[J]. 中国医药导报, 2023, 20(26): 11-15.
WEI Yongqiang1 GAO Zhan2 GAO Qinghe3 CHEN Haote4 LI Ming1 CHENG Pengyu1. Study on the medication rule of Chinese materia medica compound prescription in the treatment of spermatorrhea based on national patent. 中国医药导报, 2023, 20(26): 11-15.
京公网安备 11010502046598号